Kepley BioSystems Presents Sustainable Crayfish Biology at BugFest 2018

Each year over 35,000 visitors come to BugFest to experience over 100 exhibits, crafts, games and activities. The venue provides the opportunity for attendees to interact with entomologists, scientists and learn about the fascinating world of bugs.

2018 Theme Arthropod: Crayfish and Other Crustaceans

Cammie the Crawfish Presents: Sustainable Science and Technologies- Come and meet Cammie and learn about how she is helping to protect the environment and preserve ancient species! Cammie is a Rocky River Crayfish raised in KBI labs in Greensboro, N.C.

Pictured holding an American Lobster and OrganoBait™, a synthetic and sustainable alternative bait that attracts crustaceans funded by the National Science Foundation, North Carolina Sea Grant and One N.C. Small Business Program.

Anthony Dellinger, PhD and President of Kepley BioSystems will be speaking in the SECU Daily Planet Theater at Bugfest 2018 on Saturday, October 20, 2018 at 10:30AM.

GREENSBORO, NORTH CAROLINA, UNITED STATES, October 15, 2018 /EINPresswire.com/ — Kepley BioSystems (KBI) is pleased to have been selected for a BugFest 2018 presentation and corporate participant. BugFest is hosted by the North Carolina Museum of Natural Sciences and attracts over 35,000 visitors to experience exhibits, crafts, games and activities every year. The event brings scientists and the public together to learn and experience the remarkable world of bugs! The festival will be held on Saturday, October 20, 2018, in Raleigh, North Carolina. The Kepley presentation is scheduled for 10:30 am in the SECU Daily Planet Theater in the Nature Research Center.

The BugFest theme this year is “Arthropods – Crayfish and Other Crustaceans”; crayfish will be featured along with other arthopods, including insects, arachnids, and myriapods. KBI President, Dr. Anthony Dellinger, will kick off the presentations with a talk entitled, “Who’s Your Crawdaddy? Capturing Crayfish While Saving the World’s Baitfish.” This story of science and nature will highlight how the tiny crayfish is helping advance research to sustainably restore the ocean’s most vital resource – forage fish.

Members of the KBI team will be on hand to meet with visitors at the exhibit, “Cammie the Crawfish Presents: Sustainable Science and Technologies” (Nature Research Center – 3rd Floor, Booth #104). Cammie the Crawfish will be the featured guest, and visitors can learn how she is helping protect the environment and preserve vital ocean species.

“Kepley BioSystems is excited to participate in BugFest this year, particularly with the emphasis on arthropods. We’re looking forward to sharing our technologies – and to introducing our ten-legged team member, Cammie, to the public!” said KBI research scientist, Lee Robertson.

This year’s event will include Café Insecta where patrons will be introduced to the practice of eating bugs prepared by local chefs. In all, more than 100 exhibits will offer entomology-based education, crafts and games sure to entertain even the most entophobic visitors.

Members of the public are invited to the 2018 BugFest on October 20, 2018, at The North Carolina Museum of Natural History located at 11 West Jones Street, Raleigh, NC 27601. Admission is free. Parking is available in six lots nearby, and free street parking will also be available throughout the city on the day of the event. With more than 30,000 people expected again this year, visitors are encouraged to consider alternative transit options (https://naturalsciences.org/calendar/bugfest/getting-here-and-parking/).

# # #

About The North Carolina Museum of Natural History
The North Carolina Museum of Natural Sciences in downtown Raleigh (11 and 121 W. Jones St.) is an active research institution that engages visitors of every age and stage of learning in the wonders of science and the natural world. Hours: Mon.– Sat., 9 a.m.–5 p.m., and Sun., noon–5 p.m. General admission is free. Visit the Museum online at www.naturalsciences.org. Emlyn Koster, PhD, Museum Director. BugFest is the largest bug-centric event in the country.

About Kepley BioSystems

Kepley BioSystems (KBI) is a North Carolina-based life sciences start-up operating out of Gateway University Research Park (GURP) in collaboration with the Joint School of Nanoscience and Nanoengineering (JSNN), comprised of a partnership between the North Carolina Agriculture and Technical State University (NCA&T) and the University of North Carolina at Greensboro (UNCG). KBI was founded in 2013 with a mission to emerge disruptive innovations to achieve global solutions. For more information, visit: http://www.kepleybiosystems.com/

Anthony Dellinger
Kepley BioSystems Incorporated
(703)675-0277
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Meet Cammie, the KBI Crayfish


Source: EIN Presswire

Aspen Regenerative Medicine Now Offering Umbilical Cord Stem Cells for Osteoarthritis

With new research supporting the effectiveness of umbilical cord stem cells on osteoarthritis, we take it as our responsibility to give patients the power to overcome this debilitating condition.”

— Dr. Julian Gershon

ASPEN, COLORADO, UNITED STATES, October 15, 2018 /EINPresswire.com/ — At the Aspen Institute of Anti-Aging and Regenerative Medicine, the latest developments in healing have been discovered by utilizing stem cell therapy in clinical treatments for osteoarthritis. The clinic offers multiple applications for stem cell treatment from skin rejuvenation to hair restoration, but one of the most significant advances in regenerative medicine is in orthopedic use. As an alternative to more aggressive treatments such as long-term medications and surgery, stem cell therapy sets the goal of restoring full mobility and function in its application with orthopedic patients. The reparative qualities in stem cells have shown positive interactions with tendon and ligament injuries and have become a popular method for healing sports injuries. For Dr. Julian Gershon, the founding practitioner of the Aspen Institute for Antiaging and Regenerative Medicine, the function that umbilical cord stem cells serve to treat joint inflammation can prove to be the key to putting an end to osteoarthritis associated joint pain.

The pain and restricted movement from osteoarthritis are due to the joint’s cartilage wearing down severely enough to result in the bones and joints grinding against each other. Dr. Gershon’s method for repairing joint cartilage and reducing inflammation is through using the healing properties of Umbilical cord blood stem cells. Using high-quality, medical grade umbilical cord cells and growth factors, to give a longer lasting effect and improve quality of life for those suffering from osteoarthritis. The mesenchymal stem cells, or MSCs, in Umbilical cord blood have the potential to regenerate articular cartilage and studies have confirmed that intra-articular injection of stem cells provide improved knee function and less pain with no adverse events. In fact, the MSCs found in Umbilical cord blood stem cells have shown an increase in knee cartilage volume, enhanced joint function and effective disease modification.

“With new research supporting the effectiveness of umbilical cord stem cells on osteoarthritis, we take it as our responsibility to give patients the power to overcome this debilitating condition,” Dr. Gershon states, reflecting on the growing influence that modern innovation has had on advancing medicine to the degree of reversing the damage from osteoarthritis. “We aim to ensure our orthopedic stem cell treatments take our patients’ safety and comfort into account, so it’s exciting to see what cell therapy can offer in giving them an option that takes both into consideration and remains effective.”

The dedication that Aspen Institute of Anti-Aging and Regenerative Medicine places into providing safe and efficient solutions to a wide array of joint issues has motivated them to give patients the opportunity to gain the upper hand over osteoarthritis. With many causes of orthopedic conditions being linked towards deteriorating cartilage, the function that umbilical cord stem cells serve to reinforce tissue is a beneficial measure that proactively rebuilds cartilage while offering pain relief to patients. The efforts that Dr. Gershon has made to incorporate umbilical cord stem cells and MSCs into treatment options have helped to reinforce Aspen Regenerative Medicine’s status as a game-changing practice that taps into the body’s regenerative qualities to assist patients in reaching their optimal health.

About Dr. Julian Robert Gershon Jr. DO, FAOASM ABAARM
Dr. Julian Robert Gershon Jr. DO, FAOASM ABAARM, founder of the Aspen Institute for Anti-Aging and Regenerative Medicine, is triple board certified in Family Medicine, Sports Medicine and Anti-Aging and Regenerative Medicine. Dr. Gershon received his medical degree from Kirksville College of Osteopathic Medicine and completed his internship at Flint Osteopathic Hospital in Flint, Michigan. He is board certified in Family Medicine and Sports Medicine by the American Osteopathic Board of Family Practice, is a fellow of the American Osteopathic Academy of Sports Medicine and served on their Board of Directors for twelve years. He served as the head team physician for University of North Texas for over twenty years, served as a resident physician at the U.S. Olympic training center in Colorado Springs, Colorado in 1993, was selected as a team physician for the U.S. Olympic Judo team from 1993-2000 and served as the team physician at the 1996 Olympics in Atlanta, Georgia and was selected to travel to Chile with the U.S. Freestyle ski team during the summer of 2006. In addition to serving as a team physician for local high schools in Northern Texas, he also covered many professional wrestling events for the WWE at their Dallas events and traveled with the Unlimited Hydroplane Racing Commission performing on-water rescue as well as attending to athletic and medical injury/illnesses for their drivers. Dr. Gershon recently was awarded a fellowship in Stem Cell therapy by the American Academy of Antiaging and Regenerative Medicine. This prestigious award signifies years of advanced stem cell training.

About Aspen Institute for Anti-Aging & Regenerative Medicine
The Aspen Institute for Antiaging & Regenerative Medicine Experience specializes in everything that anti-aging and regenerative medicine has to offer in the relaxed and beautiful mountain setting of Aspen, Colorado. With stem cell and PRP therapy, founder Dr. Julian R. Gershon, Jr., DO, FAOASM, ABAARM has personally performed regenerative therapy treatments for orthopedic procedures, hair restoration, and skin rejuvenation. Additionally, their all-inclusive program is personally tailored to each patient and includes stem cell therapy, bio-identical hormone therapy via our intensive age management program, PRP facial regeneration, PRP hair regeneration, PRP “O-shot” or “PRP P-shot” for male and female sexual function, IV nutrition and vitamin therapy with antioxidant glutathione, customized year-long vitamin and nutrient supplementation, telomere testing to determine biologic age and monitor aging process, genetic testing, food allergy analysis and an environmental toxin assessment. The Aspen Institute for Antiaging and Regenerative Medicine maintains an excellent reputation for their commitment to shifting the emphasis from disease-driven medicine to an optimal health medical practice, treating each of patients individually and safely recommending programs according to their specific situations. They strive to give each patient the experience they expect and deserve from a health professional with the goal to help patients live better and longer.

Dr. Julian Gershon
Aspen Institute for Anti-aging & Regenerative Medicine
970-201-1332
email us here


Source: EIN Presswire

Dr. Victor Vogel of the Geisinger Cancer Institute to be Featured on CUTV News Radio

LEWISBURG, PENNSYLVANIA, UNITED STATES, October 15, 2018 /EINPresswire.com/ — Breast cancer causes a complete disruption of a person’s life. It can bring significant financial hardship, family difficulties, work-related problems. Whether a patient needs surgery, radiation, chemotherapy or hormonal therapy, treating breast cancer, or any cancer for that matter, requires a holistic approach that seeks to address the emotional, psychological and spiritual needs of the patient, in addition to their treatment.

Dr. Victor Vogel is the Director of Breast Medical Oncology and Research at the Geisinger Cancer Institute. For 32 years, Dr. Vogel has stood at the forefront of academic medical oncology, dedicating his career to breast cancer clinical research.

While still a medical oncology fellow, Dr. Vogel pursued his master's degree in epidemiology, the study of the causes and risk factors of disease.

“Early in my career, I got very interested in the question of why women get breast cancer,” says Dr. Vogel.

In the 1980s, mammographic breast screening had not yet been widely implemented, but there was great interest in cancer prevention. Armed with research tools and training, Dr. Vogel joined MD Anderson in Houston, a part of the University of Texas and a huge international cancer center, where he spent ten years focused on understanding what factors in a woman's medical and social history lead to an increased risk of developing breast cancer. While at MD Anderson, Dr. Vogel established a clinic designed to recruit women who had increased risk of breast cancer.

“For 15 years, I was enrolling women in research studies to answer that question: can we reduce the risk of breast cancer in women by using a simple pill to reduce their risk?” says Dr. Vogel. “And the answer is yes, we were able to do that. In our first study we had 13,000 women and we proved that tamoxifen reduced the risk of developing breast cancer by 50 percent. We did a second study with 19,000 women, and raloxifene reduced risk and was even safer. By 2006, we had both drugs approved by the FDA for reducing breast cancer risk in high-risk women.”

Not only did these interventions reduce the risk of recurrence in early breast cancer, but tamoxifen reduced the risk of a second breast cancer in the opposite breast. That’s prevention.

After a 25-year career in clinical research, Dr. Vogel spent 16 months as the national vice president for research for the American Cancer Society, raising money for the Cancer Society and introducing people to a whole new era of cancer prevention. In 2010, Dr. Vogel joined the Geisinger Health System, a large multi-specialty group with hundreds of physicians in central Pennsylvania, as their cancer center director. Today, Dr. Vogel is the head of Geisinger’s breast cancer program where he sees patients five days a week.

“It's led me to a more complete understanding of breast cancer as a disease,” says Dr. Vogel. “In the 32 years since I finished my fellowship, breast cancer treatment has gotten very complex, but in that complexity we're now offering care that covers the holistic spectrum, all the things patients and their families need for the care of their disease. We like to think we do it pretty well.”

Dr. Vogel is board-certified in medical oncology but also in general preventive medicine and public health, making him unique among his peers.

“I thoroughly believe that breast cancer, like small pox and polio, will ultimately be prevented through a more complete understanding of its etiology and the contributing risk factors.”

CUTV News Radio will feature Dr. Victor Vogel in an interview with Doug Llewelyn on October 17th at 10am EDT.

Listen to the show on BlogTalkRadio.

If you have a question for our guest, call (347) 996-3389.

For more information on Dr. Victor Vogel, visit www.geisinger.edu

Lou Ceparano
CUTV News
(631) 850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Global Demerol (Meperidine) Sales, Revenue, Gross Margin and Market Share Forecast to 2023

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Demerol (Meperidine) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023”

PUNE, MAHARASHTRA, INDIA, October 15, 2018 /EINPresswire.com/ — Demerol (meperidine), chemically known as ethyl 1-methyl-4-phenylisonipecotate hydrochloride, is an opioid pain medication. Meperidine is used to treat moderate-to-severe pain.

Scope of the Report:
This report focuses on the Demerol (Meperidine) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
An opioid is sometimes referred to as narcotics. Opioids are drugs that act on the nervous system to relieve pain. The term opioid refers to all substances (exogenous or endogenous) with morphine-like properties.
The worldwide market for Demerol (Meperidine) is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017.

Request a sample copy at
https://www.marketresearchnest.com/report/requestsample/450118

Market Segment by Manufacturers, this report covers
• Purdue Pharma
• Egalet
• Boehringer Ingelheim
• Janssen
• Sanofi
• Sun Pharmaceuticals
• Mallinckrodt Pharmaceuticals
• Endo Pharmaceuticals
• Actavis
• Pfizer

Market Segment by Regions, regional analysis covers
• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia etc.)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
• Powder
• Liquid

Market Segment by Applications, can be divided into
• Anesthesia
• Cough Treatment
• Diarrhea Treatment

Browse full table of contents and data tables at
https://www.marketresearchnest.com/Global-Demerol-Meperidine-Market-2018-by-Manufacturers-Regions-Type-and-Application-Forecast-to-2023.html

There are 15 Chapters to deeply display the global Demerol (Meperidine) market.
Chapter 1, to describe Demerol (Meperidine) Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Demerol (Meperidine), with sales, revenue, and price of Demerol (Meperidine), in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Demerol (Meperidine), for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Demerol (Meperidine) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Demerol (Meperidine) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Order a Purchase Report Copy at
https://www.marketresearchnest.com/report/purchase/450118

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on Global industries, organizations, products, and trends.

Mr Jeet
Market Research Nest
1-240-284-8070
email us here
Visit us on social media:
Facebook
Twitter
Google+
LinkedIn


Source: EIN Presswire

Global Patient Handling Equipment Sales, Revenue, Gross Margin and Market Share Forecast to 2023

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Patient Handling Equipment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023”

PUNE, MAHARASTRA, INDIA, October 15, 2018 /EINPresswire.com/ — Patient handling in healthcare facilities such as hospitals and ambulatory surgical centers involves the use of assistive devices such as lifts, stretchers, wheelchairs, beds, trolleys, and grab rails to ensure that patients can be mobilized, transferred, or repositioned safely and to avoid the performing of high-risk manual patient handling tasks by care providers.

Scope of the Report:
This report focuses on the Patient Handling Equipment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Europe is expected to account for the largest share of the global patient handling equipment market, by region, in 2018, followed by North America. North America is projected to grow at the highest CAGR in the forecast period due to strict government regulations mandating the use of patient handling equipment.

The hospitals segment is expected to dominate the patient handling equipment market in 2016, mainly due to the rising number of disabled patients in hospitals requiring assistance.

The worldwide market for Patient Handling Equipment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017.

Request a sample copy at
https://www.marketresearchnest.com/report/requestsample/450104

Market Segment by Manufacturers, this report covers
• Arjo
• Invacare Corporation
• Handicare
• Stryker
• Hill-Rom
• Investor
• Prism Medical
• Getinge Group
• Guldmann
• Stiegelmeyer

Market Segment by Regions, regional analysis covers
• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia etc.)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
• Patient transferring and repositioning equipment
• Mobilizing equipment
• Lifting equipment
• Bath safety equipment
• Others

Market Segment by Applications, can be divided into
• Home Care Settings
• Hospitals
• Elderly Care Facilities
• Others

Browse full table of contents and data tables at
https://www.marketresearchnest.com/Global-Patient-Handling-Equipment-Market-2018-by-Manufacturers-Regions-Type-and-Application-Forecast-to-2023.html

There are 15 Chapters to deeply display the global Patient Handling Equipment market.
Chapter 1, to describe Patient Handling Equipment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Patient Handling Equipment, with sales, revenue, and price of Patient Handling Equipment, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Patient Handling Equipment, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Patient Handling Equipment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Patient Handling Equipment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Order a Purchase Report Copy at
https://www.marketresearchnest.com/report/purchase/450104

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on Global industries, organizations, products, and trends.

Mr Jeet
Market Research Nest
1-240-284-8070
email us here
Visit us on social media:
Facebook
Twitter
Google+
LinkedIn


Source: EIN Presswire

Global Erythropoietin Drugs Sales, Revenue, Gross Margin and Market Share Forecast to 2023

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Erythropoietin Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023”

PUNE, MAHARASHTRA, INDIA, October 15, 2018 /EINPresswire.com/ — Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule.

Scope of the Report:
This report focuses on the Erythropoietin Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The retail pharmacies segment dominated the erythropoietin drugs market and accounted for a major part of the overall market share. The ability of retail pharmacies to provide a large customer base for biosimilars coupled with the requirement from anemic patients for EPO drugs as a maintenance therapy is the key contributor to the dominance of this segment in the global market.

The worldwide market for Erythropoietin Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017.

Request a sample copy at
https://www.marketresearchnest.com/report/requestsample/450092

Market Segment by Manufacturers, this report covers
• F. Hoffmann-La Roche
• Amgen
• Johnson and Johnson
• Kyowa Hakko Kirin
• Hospira
• Boehringer Ingelheim
• LG Life Science
• Novartis
• Pfizer
• Daichi Sankyo
• Biocon
• Chugai Pharmaceutical
• Teva Pharmaceutical Industries
• Wanbang Biochemical Pharmaceuticals
• Ahua Pharmaceutical
• Huaxin High Biotechnology

Market Segment by Regions, regional analysis covers
• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia etc.)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
• Natural Erythropoietin
• Non-natural Erythropoietin

Market Segment by Applications, can be divided into
• Hospitals
• Retail Pharmacies
• Others

Browse full table of contents and data tables at
https://www.marketresearchnest.com/Global-Erythropoietin-Drugs-Market-2018-by-Manufacturers-Regions-Type-and-Application-Forecast-to-2023.html

There are 15 Chapters to deeply display the global Erythropoietin Drugs market.
Chapter 1, to describe Erythropoietin Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Erythropoietin Drugs, with sales, revenue, and price of Erythropoietin Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Erythropoietin Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Erythropoietin Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Erythropoietin Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Order a Purchase Report Copy at
https://www.marketresearchnest.com/report/purchase/450092

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on Global industries, organizations, products, and trends.

Mr Jeet
Market Research Nest
1-240-284-8070
email us here
Visit us on social media:
Facebook
Twitter
Google+
LinkedIn


Source: EIN Presswire

Global Dendritic Cell Cancer Vaccine Sales, Revenue, Gross Margin and Market Share Forecast to 2023

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Dendritic Cell Cancer Vaccine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023”

PUNE, MAHARASHTRA, INDIA, October 15, 2018 /EINPresswire.com/ — Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.

Scope of the Report:
This report focuses on the Dendritic Cell Cancer Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Dendritic Cell Cancer Vaccine is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017.

Request a sample copy at
https://www.marketresearchnest.com/report/requestsample/450122

Market Segment by Manufacturers, this report covers
• Medigene
• Activarti
• Argos Therapeutics
• Batavia Bioservices
• Bellicum Pharmaceuticals
• Creagene
• DanDrit Biotech
• DCPrime
• Sanpower Corporation (Dendreon)
• Elios Therapeutics
• Immunicum
• Kiromic
• Merck
• Northwest Biotherapeutics
• Glaxo Smith Kline
• ImmunoCellular
• Tella
• Vaxil Bio
• Medigene

Market Segment by Regions, regional analysis covers
• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia etc.)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
• CreaVax
• Sipuleucel-T (Provenge)
• Others

Market Segment by Applications, can be divided into
• Pediatrics
• Adults

Browse full table of contents and data tables at
https://www.marketresearchnest.com/Global-Dendritic-Cell-Cancer-Vaccine-Market-2018-by-Manufacturers-Regions-Type-and-Application-Forecast-to-2023.html

There are 15 Chapters to deeply display the global Dendritic Cell Cancer Vaccine market.
Chapter 1, to describe Dendritic Cell Cancer Vaccine Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Dendritic Cell Cancer Vaccine, with sales, revenue, and price of Dendritic Cell Cancer Vaccine, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Dendritic Cell Cancer Vaccine, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Dendritic Cell Cancer Vaccine market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Dendritic Cell Cancer Vaccine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Order a Purchase Report Copy at
https://www.marketresearchnest.com/report/purchase/450122

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on Global industries, organizations, products, and trends.

Mr Jeet
Market Research Nest
1-240-284-8070
email us here
Visit us on social media:
Facebook
Twitter
Google+
LinkedIn


Source: EIN Presswire

Global Dermatological Drugs Sales, Revenue, Gross Margin and Market Share Forecast to 2023

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Dermatological Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023”

PUNE, MAHARASHTRA, INDIA, October 15, 2018 /EINPresswire.com/ — Dermatology is a field of medicine that is engaged in the diagnosis, prevention, and treatment of various skin, nails, hair diseases, pigmentation, acne, wrinkles, psoriasis, and others.

Scope of the Report:
This report focuses on the Dermatological Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Different techniques are used in dermatology such as topical and systemic medications, laser therapy, radio therapy, photodynamic therapy, vitiligo surgery, dermatological surgery, and others.
The worldwide market for Dermatological Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017.

Request a sample copy at
https://www.marketresearchnest.com/report/requestsample/450127

Market Segment by Manufacturers, this report covers
• Bayer
• Johnson and Johnson
• Pfizer
• Novartis
• GlaxoSmithKline
• AstraZeneca
• Galderma
• Amgen
• AbbVie
• Merck

Market Segment by Regions, regional analysis covers
• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia etc.)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
• Prescription-Based Drugs
• Over-the-Counter Drugs

Market Segment by Applications, can be divided into
• Acne
• Skin Infections
• Psoriasis
• Dermatitis Drugs
• Other

Browse full table of contents and data tables at
https://www.marketresearchnest.com/Global-Dermatological-Drugs-Market-2018-by-Manufacturers-Regions-Type-and-Application-Forecast-to-2023.html

There are 15 Chapters to deeply display the global Dermatological Drugs market.
Chapter 1, to describe Dermatological Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Dermatological Drugs, with sales, revenue, and price of Dermatological Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Dermatological Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Dermatological Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Dermatological Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Order a Purchase Report Copy at
https://www.marketresearchnest.com/report/purchase/450127

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on Global industries, organizations, products, and trends.

Mr Jeet
Market Research Nest
1-240-284-8070
email us here
Visit us on social media:
Facebook
Twitter
Google+
LinkedIn


Source: EIN Presswire

The Mars Generation Names Ken Buckler As Student Space Ambassador Board Chair

Ken Buckler TMG SSA Chair

Today’s students and young professionals will be the leaders of tomorrow, paving the road to Mars and beyond. We must inspire them and help them discover themselves and their leadership potential.””

— Ken Buckler

MINNEAPOLIS, MN, UNITED STATES, October 12, 2018 /EINPresswire.com/ — The Mars Generation (TMG) is pleased to announce the selection of Ken Buckler as the new chair of the Student Space Ambassador Leadership Program Advisory Board. The board members represent a partnership between students and professional leaders from the nonprofit, education and business sectors.

Ken Buckler graduated from Mount Saint Mary’s University in 2006 with a Bachelor’s in Computer Science. With a career focused on cyber security and risk management, Ken currently holds a CompTIA Advanced Security Practitioner certification.

Over the past ten years working for several contracting businesses in the United States, Ken has provided information technology and cyber security services to multiple Federal agencies, including system engineering, application security, and continuous monitoring services. He specializes in analyzing and reporting security information for large, distributed enterprises.

“Mars is a critical stepping stone in a much larger journey we must eventually embark upon to leave our solar system.” states Ken, “While in the short-term space exploration has resulted in many beneficial advances in technology on Earth, in the long-term it is absolutely critical to our survival as a species. Today’s students and young professionals will be the leaders of tomorrow, paving the road to Mars and beyond. We must inspire them and help them discover themselves and their leadership potential.”

The focus of the advisory board will continue to be the growth and enhancement of the Student Space Ambassador Leadership Program (SSA). The SSA Advisory Board will help lead efforts to build a stronger tomorrow by energizing youth today about science, technology, engineering, arts, math (STEAM) and space while also educating youth and adults about the importance of both to humankind.

About The Mars Generation Student Space Ambassador Leadership Program

The Mars Generation Student Space Ambassador Leadership Program was created to inspire, support and mentor the next generation of leaders in science, technology, engineering, arts and mathematics (STEAM) and the space-related industries. The program serves as a mentorship and leadership program for students as well as a workforce development and recruiting program for both STEAM and space industries. The Mars Generation Student Space Ambassador Leadership Program has been credited as a major force for bringing forth our future leaders in STEAM and Space.

About The Mars Generation

The Mars Generation is a 501(c)(3) nonprofit in the United States. The organization is volunteer-driven with a board of directors that includes astronauts, engineers, scientists and professionals from the nonprofit and business communities. With a reach of more than 40 million people in the organization’s first three years of operation, over one million followers on social media, over 1500 students from around the world participating in its Student Space Ambassador Leadership program, over 600 donors, 1200 members and several space industry sponsors in place, the organization continues to grow and offer programs to excite and educate students and adults about the importance of human space exploration and STEAM education.

For more information on The Mars Generation go to: TheMarsGeneration.org

Yvonne Hundshamer
The Mars Generation
612-670-0337
email us here


Source: EIN Presswire

DNAtix and Biologix are launching a Genetic DNA Sequencing pilot in Nigeria based on Blockchain

Digital DNAtix Ltd.

DNAtix

DNAtix Genetic Token

DNAtix Genetic Token

BioLogix

BioLogix

DNAtix, the blockchain genetics company, and Biologix, have announced their intention to launch a pilot for Blockchain based full genome sequencing.

RAMAT GAN, TEL AVIV, ISRAEL, October 12, 2018 /EINPresswire.com/ — Digital DNAtix Ltd., the blockchain genetics company, and Biologix, a molecular research support service provider company, have announced their intention to launch a pilot for blockchain based full genome sequencing. Biologix will use DNAtix genetic wallet to provide users with access to secure and anonymous full genome sequencing and delivering advanced genetic services. Biologix has been operating for the last 10 years in Nigeria providing support for molecular research laboratories and empowering local scientists/technologists through training and capacity building in molecular biology techniques. DNAtix considers this a step further in growing the global genetic ecosystem that will enable users to share and explore their genetic makeup in utterly new ways while maintaining full control of their data. The genetics ecosystem that DNAtix is developing will link users that are seeking genetically-tailored health and lifestyle solutions with products and services providers that fit their needs and will also enable users to participate in research and be rewarded.
"We believe that the genetic ecosystem which is based on decentralized blockchain technologies will grant users the ability to regain control of their genetic information and self-manage it”. said Ofer A. Lidsky, CEO of DNAtix. “Users should be able to decide what to do with their most private information which is their genetic make-up and if interested to monetize it and be rewarded for sharing it,” Ofer added.
“We think that in order to create a diversified and global genetic ecosystem we should enable users from different parts of the globe to access advanced genetic services which are blockchain based”. Said Galit Raiman COO and VP Marketing at DNAtix. “With a first pilot being launched in India and a second one in Nigeria and in the near future in Israel and the US, DNAtix is building the infrastructure for the genetic ecosystem” Galit added.
As of today, there are few medical geneticists and genetic counselors working in Nigeria. Most patients with genetic disorders are seen by pediatricians and some by specialists. Facilities for molecular diagnosis (including prenatal diagnosis) are suboptimal and are not widely available throughout the country (1). Biologix and DNAtix believe that as prices for genome sequencing (Exome or full genome) are dropping providing access to digital genetic services in Nigeria is now getting closer. Participants in the pilot will use DNAtix blockchain based services for highly secured and anonymous genetic service.
"Direct-to-consumer genetic tests have truly come to stay. The secure and private DNAtix platform driven by blockchain will further increase global access towards precise and personalized medicine’’ Said Dr. Voke Toye the Founder and Chief Executive of Biologix Support Services Ltd, Lagos Nigeria.
ABOUT Biologix
Biologix provides molecular research support services to the emerging biotech industry in Nigeria. For the past 10 years, we have built a strong customer base in the medical research laboratories in Nigeria with our flagship pipette management services.
We now offer training and capacity building in molecular biology techniques to students and researchers. This will foster the desired knowledge base, innovation and the right skill set that will strengthen the Nigerian bio-economy.
ABOUT DNAtix
DNAtix is developing the future blockchain-based ecosystem for genetics. With two successful proof of concept experiments already completed for transferring DNA sequences using blockchain technology and a working prototype of the genetic wallet, DNAtix is leading the world of genetic blockchain technology. www.dnatix.com
References
1. Adebowale A. Adeyemo et al. Mol Genet Genomic Med. 2018 May; 6(3): 314–321.

Galit Lidsky Raiman
Digital DNAtix Ltd.
1-818-232-3550
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire